Investigating dynamics of machine tool spindles under operational conditions

Chatter is one of the major problems in machining and can be avoided by stability diagrams which are generated using frequency response functions (FRF) at the tool tip. During cutting operations, discrepancies between the stability diagrams obtained by using FRFs measured at the idle state and the actual stability of the process are frequently observed. These deviations can be attributed to the changes of machine dynamics under cutting conditions. In this paper, the effects of the cutting process on the spindle dynamics are investigated both experimentally and analytically. The variations in the spindle dynamics are attributed to the changes in the bearing parameters. FRFs under cutting conditions are obtained through the input-output relations of the cutting forces and the vibration response which are measured simultaneously. Experimentally and analytically obtained FRFs are then used in the identification of the bearing parameters under cutting conditions. Thus, bearing properties obtained at idle and cutting conditions are compared and variations in their values are obtained

More about on the mass of the new charmonium states

If the $X(3872)$ is described by the picture as a mixture of the charmonium and molecular $D^{\ast} D$ states; $Y(3940)$ as a mixture of the $\chi_{c0}$ and $D^\ast D^\ast$ states; and $X(4260)$ as a mixture of the tetra-quark and charmonium sates, their orthogonal combinations should also exist. We estimate the mass and residues of the states within the QCD sum rules method. We find that the mass splitting among $X$, $Y$ and their orthogonal states is at most $200MeV$. Experimental search of these new states can play critical role for establishing the nature of the new charmonium states.Comment: 12 pages, 6 figures, LaTeX formatte

Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study

Background: Trastuzumab (T) combined with chemotherapy has been recently shown to improve outcome in HER2-positive breast cancer (BC). The aim of this study was to evaluate the toxic effects of concurrent radiation therapy (RT) and T administration in the adjuvant setting. Patients and methods: Data of 146 patients with stages II-III HER2-positive BC were recorded. Median age was 46 years. In all, 32 (23%) and 114 (77%) patients received a weekly and a 3-week T schedule, respectively. A median dose of 50 Gy was delivered after surgery. Internal mammary chain (IMC) was irradiated in 103 (71%) patients. Results: Grade >2 dermatitis and esophagitis were noted in 51% and 12%, respectively. According to the Common Toxicity Criteria v3.0 scale and HERA (HERceptin Adjuvant) trial criteria, respectively, 10% and 6% of the patients had a grade ≥2 of left ventricular ejection fraction (LVEF) decrease after RT. Multivariate analyses revealed two independent prognostic factors: weekly T administration (for LVEF decrease) and menopausal status (for dermatitis). Higher level of T cumulative dose (>1600 mg) was only borderline of statistical significance for acute esophagitis toxicity. Conclusion: We showed that weekly concurrent T and RT are feasible in daily clinical practice with, however, a decrease of LVEF. Cardiac volume sparing and patient selections for IMC irradiation are highly recommended. Longer follow-up is warranted to evaluate late toxic effect

Assessing the decarbonization of electricity generation in major emitting countries by 2030 and 2050: Transition to a high share renewable energy mix

The urgent need to mitigate the severe environmental impacts of climate change necessitates a transition to a low-carbon energy infrastructure, crucial for decarbonization and achieving global sustainability goals. This study investigates the decarbonization trajectories of five major economies and significant carbon emitters: the United States of America (USA), China, Japan, Germany, and India. We focus on evaluating two decarbonization scenarios for power generation. Scenario 1 explores the use of a generic storage system for reducing critical excess electricity production (CEEP), maintaining the same thermal power plant capacity as in the reference year 2021. In contrast, Scenario 2 models thermal power plants to meet the exact electricity demand without introducing a new electricity storage system. The primary aim is to assess the feasibility and implications of achieving a 100% share of renewable and nuclear energy by 2030 and 2050 in these countries. EnergyPLAN software was utilized to model and simulate the electricity systems of these countries. The two scenarios represent different degrees of renewable energy integration, demonstrating possible transitional pathways towards an environmentally friendly electricity generation system. The study provides a comparative analysis of the outcomes for each country, focusing on carbon emissions reduction and the impact on annual total costs in 2030 and 2050. Results show that by 2030, China could reduce its emissions by 88.5% and 85.14% in Scenarios 1 and 2, relative to 2021 levels. From the two scenarios considered in all the countries, India records the highest percentage reduction while Germany has the least percentage emission in reference to 2021, with a potential decrease of 90.63% and 52.42% respectively. By 2050, carbon emissions in the USA will be reduced by 83% and 79.8% using Scenario 1 and Scenario 2 decarbonization pathways. This research significantly contributes to understanding the decarbonization potential of global electricity generation. It provides vital data for policymakers, energy planners, and stakeholders involved in developing sustainable energy policies

Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.

The abscopal effect describes the ability of locally administered radiotherapy to induce systemic antitumor effects. Although mentioned for the first time in the 1950s, records of abscopal effects, considered to be immune-mediated, are scarce with radiotherapy alone. However, with the continued development and use of immunotherapy, reports on the abscopal effect have become increasingly frequent during the last decade. Here, we report a patient with advanced malignant pleural mesothelioma who had progressive disease while on the anti-PDL1 inhibitor pembrolizumab and showed an abscopal response after palliative radiotherapy

Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey†

Predicting breast cancer outcome based on SLN node status without ALND is currently an area of uncertainty in SLN+ patients. These uncertainties influence the decision-making of adjuvant nodal irradiation. The NORA Survey was designed to examine the patterns of RNI practice in Europe to provide a basis for designing future trials in areas of equipoise in clinical decision-making concerning RN

Lymphoid Enhancer Factor-1 Links Two Hereditary Leukemia Syndromes through Core-binding Factor α Regulation of ELA2

Two hereditary human leukemia syndromes are severe congenital neutropenia (SCN), caused by mutations in the gene ELA2, encoding the protease neutrophil elastase, and familial platelet disorder with acute myelogenous leukemia (AML), caused by mutations in the gene AML1, encoding the transcription factor core-binding factor α (CBFα). In mice, CBFα regulates the expression of ELA2, suggesting a common link for both diseases. However, gene-targeted mouse models have failed to reproduce either human disease, thus prohibiting further in vivo studies in mice. Here we investigate CBFα regulation of the human ELA2 promoter, taking advantage of bone marrow obtained from patients with either illness. In particular, we have identified novel ELA2 promoter substitutions (-199 C to A) within a potential motif for lymphoid enhancer factor-1 (LEF-1), a transcriptional mediator of Wnt/β-catenin signaling, in SCN patients. The LEF-1 motif lies adjacent to a potential CBFα binding site that is in a different position in human compared with mouse ELA2. We find that LEF-1 and CBFα co-activate ELA2 expression. In vitro, the high mobility group domain of LEF-1 interacts with the runt DNA binding and proline-, serine-, threonine-rich activation domains of CBFα. ELA2 transcript levels are up-regulated in bone marrow of an SCN patient with the -199 C to A substitution. Conversely, a mutation of the CBFα activation domain, found in a patient with familial platelet disorder with AML, fails to stimulate the ELA2 promoter in vitro, and bone marrow correspondingly demonstrates reduced ELA2 transcript. Observations in these complementary patients indicate that LEF-1 cooperates with CBFα to activate ELA2 in vivo and also suggest the possibility that up-regulating promoter mutations can contribute to SCN. Two hereditary AML predisposition syndromes may therefore intersect via LEF-1, potentially linking them to more generalized cancer mechanisms

History of the rare cancer network and past research.

Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents. The network held its first international symposium in Nice, France, on March 21-22, 2014. The proceedings of that meeting are presented in two companion papers. This manuscript reviews the history of the growth of the RCN and contains the abstracts of fourteen oral presentations made at the meeting of prior RCN studies. From 1993 to 2014, 74 RCN studies have been initiated, of which 54 were completed, 10 are in progress or under analysis, and 9 were stopped due to poor accrual. Forty-four peer reviewed publications have been written on behalf of the RCN

Multidisciplinary approach of early breast cancer: The biology applied to radiation oncology

Early breast cancer treatment is based on a multimodality approach with the application of clinical and histological prognostic factors to determine locoregional and systemic treatments. The entire scientific community is strongly involved in the management of this disease: radiologists for screening and early diagnosis, gynecologists, surgical oncologists and radiation oncologists for locoregional treatment, pathologists and biologists for personalized characterization, genetic counselors for BRCA mutation history and medical oncologists for systemic therapies